Taking Stock of Most-Favored Nation Deals: How Have Markets Reacted?

Clicks: 1
ID: 320295
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #70 of 89 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Objective The Trump Administration has pursued most-favored nation (MFN) drug pricing agreements with major pharmaceutical manufacturers, raising concerns about potential effects on pharmaceutical revenues, profitability, and innovation incentives. We examined whether equity markets interpreted these developments as positive or negative for the pharmaceutical sector. Methods We conducted an event study of 16 publicly traded pharmaceutical firms announcing MFN agreements. Abnormal returns (ARs) and cumulative abnormal returns (CARs) were estimated using standard market-model regressions based on each firm’s historical relationship to the S&P 500. We analyzed market reactions surrounding “Liberation Day,” the date MFN letters were announced, and subsequent agreement announcements. Results The strongest market response was observed following the first MFN agreement announced by Pfizer, with largely positive market reactions across most of the pharmaceutical firms analyzed. In contrast, “Liberation Day” generated limited market reaction, while the MFN letters produced more modest negative effects. Conclusions Investors did not interpret the announced MFN agreements as materially value-destructive, likely because the deals primarily targeted Medicaid and the limited TrumpRx platform, while also resolving some regulatory and tariff uncertainty. Future expansion of MFN may lead to different market reactions.
Reference Key
openalex_W7167832322 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Noam Y. Kirson, John M Dooley, Zhiqing Ge, Amitabh Chandra
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag176
URL
https://doi.org/10.1093/haschl/qxag176
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.